Skip to main content

Advertisement

SpringerLink
Log in

The use of combination therapy in the treatment of postmenopausal osteoporosis

  • Review
  • Published:
Endocrine Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

In recent years, there has been growing interest in the potential use of combination therapy in the management of osteoporosis in postmenopausal women. Possible regimens include sequential or combined use of anti-resorptive drugs or combinations of anabolic and anti-resorptive agents, given concurrently or in sequence. Combined therapy with anti-resorptive drugs usually produces greater increases in bone mineral density (BMD) than monotherapy but there is no evidence that this results in greater anti-fracture efficacy. The use of bisphosphonates before strontium ranelate or PTH peptides blunts the BMD response. Combined PTH and anti-resorptive therapy results in more rapid gains in spine BMD and a greater increase in hip BMD than PTH monotherapy in the first year of treatment but greater gains in both spine and hip BMD are seen with PTH monotherapy than combined therapy after 2 years of treatment. Anti-resorptive therapy after PTH therapy maintains or increases the gains in BMD. Further research is required to establish the cost-effectiveness and safety of combined and sequential regimens.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. J.E. Compston, N.B. Watts, Combination therapy for postmenopausal osteoporosis. Clin. Endo. 56, 565–569 (2002)

    Article  CAS  Google Scholar 

  2. S.J. Wimalawansa, Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study. Am. J. Med. 99, 36–42 (1995)

    Article  PubMed  CAS  Google Scholar 

  3. S.J. Wimalawansa, A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am. J. Med. 104, 219–226 (1998)

    Article  PubMed  CAS  Google Scholar 

  4. R. Lindsay, F. Cosman, R.A. Lobo, B.W. Walsh, S.T. Harris, J.E. Reagan, C.L. Liss, M.E. Melton, C.A. Byrnes, Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J. Clin. Endocrinol. Metab. 84, 3076–3081 (1999)

    Article  PubMed  CAS  Google Scholar 

  5. H.G. Bone, S.L. Greenspan, C. McKeever, N. Bell, M. Davidson, R.W. Downs, R. Emkey, P.J. Meunier, S.S. Miller, A.L. Mulloy, R.R. Recker, S.R. Weiss, N. Heyden, T. Musliner, S. Suryawanshi, A.J. Yates, A. Lombardi, Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/estrogen study group. J. Clin. Endocrinol. Metab. 85, 720–726 (2000)

    Article  PubMed  CAS  Google Scholar 

  6. S.L. Greenspan, N.M. Resnick, R.A. Parker, Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women. J. Am. Med. Assoc. 289, 2525–2533 (2003)

    Article  CAS  Google Scholar 

  7. S.T. Harris, E.F. Eriksen, M. Davidson, M.P. Ettinger, A.H. Moffett Jr, D.J. Baylink, C.E. Crusan, A.A. Chines, Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J. Clin. Endocrinol. Metab. 86, 1890–1897 (2001)

    Article  PubMed  CAS  Google Scholar 

  8. O. Johnell, W.H. Scheele, Y. Lu, J.Y. Reginster, A.G. Need, E. Seeman, Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J. Clin. Endocrinol. Metab. 87, 985–992 (2002)

    Article  PubMed  CAS  Google Scholar 

  9. N.B. Watts, M. Notelovitz, M.C. Timmons, W.A. Addison, B. Wiita, L.J. Downey, Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause. Obstet. Gynecol. 85, 529–537 (1995)

    Article  PubMed  CAS  Google Scholar 

  10. M. Meschia, M. Brincat, P. Barbacini, P.G. Crossignani, W. Albisetti, A clinical trial on the effects of a combination of elcatonin (carbocalcitonin) and conjugated estrogens on vertebral bone mass in early postmenopausal women. Calcif. Tissue Int. 53, 17–20 (1993)

    Article  PubMed  CAS  Google Scholar 

  11. M. Tuppurainen, K. Härmä, M. Komulainen, V. Kiviniemi, H. Kröger, R. Honkanen, E. Alhava, J. Jurvelin, S. Saarikoski, Effects of continuous combined hormone replacement therapy and clodronate on bone mineral density in osteoporotic postmenopausal women: a 5-year follow-up. Maturitas 66, 423–430 (2010)

    Article  PubMed  CAS  Google Scholar 

  12. D.L. Kendler, C. Roux, C.L. Benhamou, J.P. Brown, M. Lillestol, S. Siddhanti, H.S. Man, J.S. Martin, H.G. Bone, Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J. Bone. Miner. Res. 25, 72–81 (2010)

    Article  PubMed  CAS  Google Scholar 

  13. J.Y. Reginster, R. Deroisy, M. Dougados, I. Jupsin, J. Colette, C. Roux, Prevention of early postmenopausal bone loss by strontium ranelate: the randomised, two-year, double-masked, dose-ranging, placebo-controlled PREVOS study. Osteoporos. Int. 13, 925–931 (2002)

    Article  PubMed  CAS  Google Scholar 

  14. P.J. Meunier, D.O. Slosman, P.D. Delmas, J.L. Sebert, M.L. Brandi, C. Albanese, R. Lorenc, S. Pors-Neilsen, M.C. de Vernejoul, A. Roces, J.Y. Reginster, Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis–a 2-year randomised placebo controlled trial. J. Clin. Endocrinol. Metab. 87, 2060–2066 (2002)

    Article  PubMed  CAS  Google Scholar 

  15. G.M. Blake, J.E. Compston, I. Fogelman, Could strontium ranelate have a synergistic role in the treatment of osteoporosis? J. Bone Miner. Res. 24, 1354–1357 (2009)

    Article  PubMed  CAS  Google Scholar 

  16. E.T. Middleton, S.A. Steel, M. Aye, S.M. Doherty, The effect of prior bisphosphonate therapy on the subsequent BMD and bone turnover response to strontium ranelate. J. Bone Miner. Res. 25, 455–462 (2010)

    Article  PubMed  CAS  Google Scholar 

  17. E.T. Middleton, S.A. Steel, M. Aye, S.M. Doherty, The effect of prior bisphosphonate therapy on the subsequent therapeutic effects of strontium ranelate over 2 years. Osteoporos. Int. 19(12), 1811–1812 (2011)

    Google Scholar 

  18. B. Ettinger, J. San Martin, G. Crans, I. Pavo, Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J. Bone Miner. Res. 19, 745–751 (2004)

    Article  PubMed  CAS  Google Scholar 

  19. F. Cosman, J. Nieves, L. Woelfert, V. Shen, R. Lindsay, Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J. Bone Miner. Res. 13, 1051–1055 (1998)

    Article  PubMed  CAS  Google Scholar 

  20. F. Cosman, R.A. Wermers, C. Recknor, K.F. Mauck, L. Xie, E.V. Glass, J.H. Krege, Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J. Clin. Endocrinol. Metab. 94, 3772–3780 (2009)

    Article  PubMed  CAS  Google Scholar 

  21. F. Cosman, J. Nieves, M. Zion, L. Woelfert, M. Luckey, R. Lindsay, Daily and cyclic parathyroid hormone in women receiving alendronate. N. Engl. J. Med. 353, 566–575 (2005)

    Article  PubMed  CAS  Google Scholar 

  22. P.D. Miller, P.D. Delmas, R. Lindsay, N.B. Watts, M. Luckey, J. Adachi, K. Saag, S.L. Greenspan, E. Seeman, S. Boonen, S. Meeves, T.F. Lang, J.P. Bilezikian, Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J. Clin. Endocrinol. Metab. 93, 3785–3793 (2008)

    Article  PubMed  CAS  Google Scholar 

  23. B.M. Obermayer-Pietsch, F. Marin, E.V. McCloskey, P. Hadji, J. Farrerons, S. Boonen, M. Audran, C. Barker, A.D. Anastasilakis, W.D. Fraser, T. Nickelsen, EUROFORS Investigators, Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J. Bone Miner. Res. 23, 1591–1600 (2008)

    Article  PubMed  CAS  Google Scholar 

  24. S. Boonen, F. Marin, B. Obermayer-Pietsch, M.E. Simões, C. Barker, E.V. Glass, P. Hadji, G. Lyritis, H. Oertel, T. Nickelsen, E.V. McCloskey, EUROFORS Investigators, Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J. Clin. Endocrinol. Metab. 93, 852–860 (2008)

    Article  PubMed  CAS  Google Scholar 

  25. R. Lindsay, J. Nieves, C. Formica, E. Henneman, L. Woelfert, V. Shen, D. Dempster, F. Cosman, Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350, 550–555 (1997)

    Article  PubMed  CAS  Google Scholar 

  26. F. Cosman, J. Nieves, L. Woelfert, C. Formica, S. Gordon, V. Shen, R. Lindsay, Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J. Bone Miner. Res. 16, 925–931 (2001)

    Article  PubMed  CAS  Google Scholar 

  27. R. Prince, A. Sipos, A. Hossain, U. Syversen, S. Ish-Shalom, E. Marcinowska, J. Halse, R. Lindsay, G.P. Dalsky, B.H. Mitlak, Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J. Bone Miner. Res. 20, 1507–1513 (2005)

    Article  PubMed  CAS  Google Scholar 

  28. D.M. Black, J.P. Bilezikian, K.E. Ensrud, S.L. Greenspan, L. Palermo, T. Hue, T.F. Lang, J.A. McGowan, C.J. Rosen, One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N. Engl. J. Med. 353, 555–565 (2005)

    Article  PubMed  CAS  Google Scholar 

  29. B.Z. Leder, R.M. Neer, J.J. Wyland, H.W. Lee, S.M. Burnett-Bowie, J.S. Finkelstein, Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis. J. Clin. Endocrinol. Metab. 94, 2915–2921 (2009)

    Article  PubMed  CAS  Google Scholar 

  30. R. Lindsay, W.H. Scheele, R. Neer, G. Pohl, S. Adami, C. Mautalen, J.Y. Reginster, J.J. Stepan, S.L. Myers, B.H. Mitlak, Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch. Intern. Med. 164, 2024–2030 (2004)

    Article  PubMed  Google Scholar 

  31. R.S. Rittmaster, M. Bolognese, M.P. Ettinger, D.A. Hanley, A.B. Hodsman, D.L. Kendler, C.J. Rosen, Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J. Clin. Endocrinol. Metab. 85, 2129–2134 (2000)

    Article  PubMed  CAS  Google Scholar 

  32. R. Eastell, T. Nickelsen, F. Marin, C. Barker, P. Hadji, J. Farrerons, M. Audran, S. Boonen, K. Brixen, J.M. Gomes, B. Obermayer-Pietsch, A. Avramidis, G. Sigurdsson, C.C. Glüer, Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J. Bone Miner. Res. 24, 726–736 (2009)

    Article  PubMed  CAS  Google Scholar 

  33. E.S. Kurland, S.L. Heller, B. Diamond, D.J. McMahon, F. Cosman, J.P. Bilezikian. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone (1–34)]. Osteoporos. Int. 15, 992–997 (2004)

    Google Scholar 

  34. P.D. Delmas, P. Vergnaud, M.E. Arlot, P. Pastoureau, P.J. Meunier, M.H. Nilssen, The anabolic effect of human PTH (1–34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate—is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone 16, 603–610 (1995)

    Article  PubMed  CAS  Google Scholar 

  35. C. Deal, M. Omizo, E.N. Schwartz, E.F. Eriksen, P. Cantor, J. Wang, E.V. Glass, S.L. Myers, J.H. Krege, Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J. Bone Miner. Res. 20, 1905–1911 (2005)

    Article  PubMed  CAS  Google Scholar 

  36. D.M. Black, S.L. Greenspan, K.E. Ensrud, L. Palermo, J.A. McGowan, T.F. Lang, P. Garnero, M.L. Bouxsein, J.P. Bilezikian, C.J. Rosen, The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med. 349, 1207–1215 (2003)

    Article  PubMed  CAS  Google Scholar 

  37. J.S. Finkelstein, A. Hayes, J.L. Hunzelman, J.J. Wyland, H. Lee, R.M. Neer, The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N. Engl. J. Med. 349, 1216–1226 (2003)

    Article  PubMed  CAS  Google Scholar 

  38. J.S. Finkelstein, J.J. Wyland, H. Lee, R.M. Neer, Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 95, 1838–1845 (2010)

    Article  PubMed  CAS  Google Scholar 

  39. F. Cosman, E.F. Eriksen, C. Recknor, P.D. Miller, N. Guañabens, C. Kasperk, P. Papanastasiou, A. Readie, H. Rao, J.A. Gasser, C. Bucci-Rechtweg, S. Boonen, Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis. J. Bone Miner. Res. 26, 503–511 (2011)

    Article  PubMed  CAS  Google Scholar 

  40. S.L. Greenspan, H.G. Bone, M.P. Ettinger, D.A. Hanley, R. Lindsay, J.R. Zanchetta, C.M. Blosch, A.L. Mathisen, S.A. Morris, T.B. Marriott, Treatment of Osteoporosis with Parathyroid Hormone Study Group, Effect of recombinant human parathyroid hormone (1–84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann. Intern. Med. 146, 326–339 (2007)

    PubMed  Google Scholar 

  41. D.M. Black, S.R. Cummings, D.B. Karpf, J.A. Cauley, D.E. Thompson, M.C. Nevitt, D.C. Bauer, H.K. Genant, W.L. Haskell, R. Marcus, S.M. Ott, J.C. Torner, S.A. Quandt, T.F. Reiss, K.E. Ensrud, Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group. Lancet 348, 1535–1541 (1996)

    Article  PubMed  CAS  Google Scholar 

  42. M.R. McClung, P. Geusens, P.D. Miller, H. Zippel, W.G. Bensen, C. Roux, S. Adami, I. Fogelman, T. Diamond, R. Eastell, P.J. Meunier, J.Y. Reginster, Hip Intervention Program Study Group, Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N. Engl. J. Med. 344, 333–340 (2001)

    Article  PubMed  CAS  Google Scholar 

  43. D.M. Black, P.D. Delmas, R. Eastell, I.R. Reid, S. Boonen, J.A. Cauley, F. Cosman, P. Lakatos, P.C. Leung, Z. Man, C. Mautalen, P. Mesenbrink, H. Hu, J. Caminis, K. Tong, T. Rosario-Jansen, J. Krasnow, T.F. Hue, D. Sellmeyer, E.F. Eriksen, S.R. Cummings, HORIZON Pivotal Fracture Trial, Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. 356, 1809–1822 (2007)

    Article  PubMed  CAS  Google Scholar 

  44. R.M. Neer, C.D. Arnaud, J.R. Zanchetta, R. Prince, G.A. Gaich, J.Y. Reginster, A.B. Hodsman, E.F. Eriksen, S. Ish-Shalom, H.K. Genant, O. Wang, B.H. Mitlak, Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344, 1434–1441 (2001)

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

JEC acknowledges support from the Cambridge Biomedical Research Centre and National Institute for Health Research (NIHR).

Author information

Authors and Affiliations

  1. Bone Medicine, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 0QQ, UK

    Juliet Compston

Authors
  1. Juliet Compston
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Juliet Compston.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Compston, J. The use of combination therapy in the treatment of postmenopausal osteoporosis. Endocrine 41, 11–18 (2012). https://doi.org/10.1007/s12020-011-9554-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-011-9554-2

Keywords

Search

Navigation